PC
RIGL icon

Paulson & Co’s Rigel Pharmaceuticals RIGL Stock Holding History

Paulson & Co’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-66,206
Closed -$1.81M – 81
2017
Q2 		$1.81M Buy
66,206
+11,206
+20% +$307K 0.02% 93
2017
Q1 		$1.82M Buy
55,000
+16,230
+42% +$414K 0.02% 85
2016
Q4 		$923K Sell
38,770
-41,730
-52% -$1.2M 0.01% 93
2016
Q3 		$2.95M Sell
80,500
-19,470
-19% -$558K 0.03% 81
2016
Q2 		$2.23M Hold
99,970
– – 0.02% 72
2016
Q1 		$2.08M Buy
99,970
+47,100
+89% +$1.16M 0.02% 81
2015
Q4 		$1.6M Buy
+52,870
New +$1.6M 0.01% 69

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Paulson & Co's RIGL Position: Q3 2017 in Review

Paulson & Co sold out of Rigel Pharmaceuticals (RIGL) in Q3 2017, closing a stake of 66,206 shares — an estimated $1.81M sold.

Paulson & Co first reported a position in RIGL in Q4 2015 and held it in 7 quarters. The position peaked at $2.95M in Q3 2016. 108 funds tracked by Wall St. Rank hold RIGL as of Q3 2017.

  • Paulson & Co reported no remaining Rigel Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Paulson & Co sold 66,206 Rigel Pharmaceuticals shares in Q3 2017, an estimated $1.81M.
  • Paulson & Co first reported a position in Rigel Pharmaceuticals in Q4 2015 and held it in 7 quarters.
  • Paulson & Co's Rigel Pharmaceuticals position peaked at $2.95M in Q3 2016.
  • 108 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2017.

Based on Paulson & Co's 13F filing for Q3 2017, filed 14 Nov 2017.